Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

3.12
-0.0400-1.27%
Post-market: 3.120.00000.00%16:10 EDT
Volume:200.43K
Turnover:633.83K
Market Cap:196.14M
PE:-2.41
High:3.30
Open:3.06
Low:3.06
Close:3.16
52wk High:4.22
52wk Low:0.6101
Shares:62.87M
Float Shares:2.50M
Volume Ratio:1.08
T/O Rate:8.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2929
EPS(LYR):-1.2929
ROE:-99.45%
ROA:-40.74%
PB:2.86
PE(LYR):-2.41

Loading ...

Prelude Therapeutics Chief Business Officer Sean P. Brusky files initial beneficial ownership statement

Reuters
·
Mar 20

Prelude Therapeutics management to meet with Citizens

TIPRANKS
·
Mar 19

Prelude Therapeutics to present PRT13722 preclinical poster at AACR Annual Meeting 2026

Reuters
·
Mar 18

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

GlobeNewswire
·
Mar 18

Prelude Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 11

Prelude Therapeutics price target raised to $6 from $3 at Citizens

TIPRANKS
·
Mar 11

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

TIPRANKS
·
Mar 10

Prelude Therapeutics Q4 EPS $(0.20) Misses $(0.03) Estimate, Sales $5.640M Miss $35.000M Estimate

Benzinga
·
Mar 10

Prelude Therapeutics reports $99.5 mln net loss for 2025

Reuters
·
Mar 10

BRIEF-Prelude Therapeutics FY EPS USD -1.29

Reuters
·
Mar 10

Press Release: Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Dow Jones
·
Mar 10

Prelude Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
Mar 06

Walmart, DoorDash And 3 Stocks To Watch Heading Into Thursday

Benzinga_recent_news
·
Feb 19

Sana Biotechnology Names Brian Piper Chief Financial Officer

Reuters
·
Feb 17

BUZZ-Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug

Reuters
·
Feb 03

BRIEF-Prelude Therapeutics Receives FDA Clearance Of Investigational New Drug Application (Ind) For Prt12396, A Mutant-Selective Jak2v617f Inhibitor

Reuters
·
Feb 03

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (Ind) for PRT12396, a Mutant-Selective Jak2v617f Inhibitor

THOMSON REUTERS
·
Feb 03

Prelude Therapeutics Inc - to Dose First Patient by Q2 2026

THOMSON REUTERS
·
Feb 03

Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology

TIPRANKS
·
Jan 27

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Jan 21